Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. Li, Y. Zhou, F. Fan, X. Li, H. Yu (Shanghai, China). Effect of azithromycin-predominant combined therapy on patients with diffuse panbronchiolitis. Eur Respir J 2009; 34: Suppl. 53, 751

Member's Comments

No comment yet.

Related content which might interest you: Diffuse panbronchiolitis Source: Eur Respir J 2008; 32: 237-238 Year: 2008 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Effects of long-term humidification therapy in bronchiectasis patients and overlap (bronchiectasis/asthma) Source: International Congress 2019 – Novel interventions and models of pulmonary rehabilitation Year: 2019 Diffuse panbronchiolitis and mimickers of bronchiolitis Source: Annual Congress 2004 - PG14 - Bronchiolitis in adults Year: 2004 Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004 Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006 Long-term macrolides in diffuse interstitial lung diseases Source: Eur Respir Rev, 26 (146) 170082; 10.1183/16000617.0082-2017 Year: 2017 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis Source: Eur Respir J 2001; 18: 753-757 Year: 2001 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020